Literature DB >> 31594212

Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.

Junqiang Zhang1,2, Gengyun Sun1, Xiaodong Mei2.   

Abstract

BACKGROUND: Family with sequence similarity 83 member A (FAM83A) can promote tumor cell proliferation and facilitate epidermal growth factor tyrosine kinase inhibitor resistance in some malignant tumors, but its role in lung cancer has not been directly explored.
OBJECTIVE: We investigated FAM83A expression in lung adenocarcinoma (LUAD) and its significance in clinicopathologic characteristics and prognosis of the disease. PATIENTS AND METHODS: We analyzed the mRNA expression of FAM83A in LUAD and normal (or adjacent) lung tissues from Oncomine database firstly. Then, we detected FAM83A protein expression in five paired fresh LUAD and adjacent lung tissue specimens from patients in our hospital by Western blotting. In addtion, FAM83A expression in 86 paraffin-embedded archived LUAD samples was evaluated by Immunohistochemistry, and the correlations between FAM83A expression and clinicopathologic characteristics and prognosis of the patients were analyzed.
RESULTS: Oncomine data analysis manifested that FAM83A mRNA expression was increased in LUAD. Western blotting revealed higher FAM83A expression in fresh LUAD tissues than in the adjacent lung tissues (P= 0.036). Immunohistochemistry analysis on 86 paraffin samples further demonstrated that the LUAD tissue had higher FAM83A expression than adjacent lung tissue (P< 0.001). The correlation analysis revealed that advanced stage tumors (stage III-IV) had higher FAM83A expression than early stage tumors (stage I-II) (P= 0.004). High FAM83A expression was significantly associated with lymphnode involvement and clinical staging (P= 0.008 and 0.008 respectively). Univariate and multivariate Cox regression analysis manifested that FAM83A expression was an independent predictive factor for poor survival. Kaplan-Meier survival curves showed that patients with higher FAM83A expression had shorter overall survival than those with lower FAM83A expressions (P= 0.002).
CONCLUSION: FAM83A is upregulated in advanced LUAD and is related to unfavorible prognosis. FAM83A might be a novel diagnostic and prognositic biomarker for LUAD.

Entities:  

Keywords:  Family with sequence similarity 83 member A (FAM83A); lung adenocarcinoma; prognositic

Mesh:

Substances:

Year:  2019        PMID: 31594212     DOI: 10.3233/CBM-190520

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  7 in total

1.  CircMIIP Contributes to Non-Small Cell Lung Cancer Progression by Binding miR-766-5p to Upregulate FAM83A Expression.

Authors:  Tao Wang; Xu Zhu; Kai Wang
Journal:  Lung       Date:  2022-01-11       Impact factor: 2.584

2.  BCAT1 promotes lung adenocarcinoma progression through enhanced mitochondrial function and NF-κB pathway activation.

Authors:  Mengdan Yu; Qianwei Zhao; Jinxia Li; Fang Xu; Zhibiao Zhang; Yixian Liu; Liping Dai; Bingxia Zhang; Jianying Zhang; Jintao Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2022 Sept 15       Impact factor: 5.552

3.  A Novel Prognostic Model of Early-Stage Lung Adenocarcinoma Integrating Methylation and Immune Biomarkers.

Authors:  Jin Ren; Yun Yang; Chuanyin Li; Lu Xie; Ronggui Hu; Xiong Qin; Menghuan Zhang
Journal:  Front Genet       Date:  2021-01-21       Impact factor: 4.599

4.  FAM83A as a Potential Biological Marker Is Regulated by miR-206 to Promote Cervical Cancer Progression Through PI3K/AKT/mTOR Pathway.

Authors:  Li Rong; Haiyu Li; Zhaodong Li; Jing Ouyang; Yongping Ma; Fangzhou Song; Yaokai Chen
Journal:  Front Med (Lausanne)       Date:  2020-12-04

5.  Combining Genetic Mutation and Expression Profiles Identifies Novel Prognostic Biomarkers of Lung Adenocarcinoma.

Authors:  Yun Liu; Fu Liu; Xintong Hu; Jiaxue He; Yanfang Jiang
Journal:  Clin Med Insights Oncol       Date:  2020-10-28

6.  Aberrant epigenetic and transcriptional events associated with breast cancer risk.

Authors:  Natascia Marino; Rana German; Ram Podicheti; Douglas B Rusch; Pam Rockey; Jie Huang; George E Sandusky; Constance J Temm; Sandra Althouse; Kenneth P Nephew; Harikrishna Nakshatri; Jun Liu; Ashley Vode; Sha Cao; Anna Maria V Storniolo
Journal:  Clin Epigenetics       Date:  2022-02-09       Impact factor: 6.551

7.  High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis.

Authors:  Chengming Tian; Xiyao Li; Chunlin Ge
Journal:  Mol Med       Date:  2021-06-16       Impact factor: 6.354

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.